News and Media

Latest News Release
01/31/2024

Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Cardinal Health Issues Nationwide Recall of Select Monoject™ Flush Prefilled Saline Syringes
08/19/2021

DUBLIN, OHIO – August 19, 2021 — On August 4, 2021, Cardinal Health (NYSE: CAH) initiated a nationwide recall of approximately 267 million MonojectTM Flush Prefilled Saline Syringes (0.9% Sodium Chloride). The products have been found to reintroduce air into the syringe after the air has been expelled. This could result in injection of air into blood vessels and create the potential for air embolism, which can cause serious adverse health outcomes or death.

Customers who have affected product(s) should immediately review their inventory and quarantine and return all affected product. The recall applies to all lots of the products manufactured from July 2019 to June 2021 distributed between July 2019 and July 2021.

The following SKUs have been recalled:

Name of Product

SKUs

12mL Syringe, 10 mL Saline Fill

8881570121

12mL Syringe, 3 mL Saline Fill

8881570123

12mL Syringe, 5 mL Saline Fill

8881570125

Our Monoject™ 3mL syringe, 2.5mL Saline Fill is not affected by this recall. This item, SKU 8881570300, will be available for sale until inventory is depleted.

MonojectTM Flush Prefilled Saline Syringes can be identified by the barrel of the syringe, the case and the box as shown in the pictures below:

 

  Barrel Print   Box Print   Case Print


The company has received 37 reports of the plunger pulling back. No injuries have been reported to date.Cardinal Health voluntarily recalled MonojectTM Flush Prefilled Saline Syringes after learning that there is potential for the syringe’s plunger to draw back and reintroduce air back into the syringe. Cardinal Health has notified the U.S. Food and Drug Administration of this action.

Cardinal Health notified its distributors and customers by overnight delivery of a notification packet on August 5, 2021 and is arranging for return of all recalled products.

Cardinal Health distributes this product nationwide.

Customers with questions may contact the market action team via telephone at 800-292- 9332 between the hours of 8 a.m. – 5 p.m. EST. Customers may also contact the team via email at GMB-FieldCorrectiveAction@cardinalhealth.com.

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program online, by mail or by fax:

Given the limited number of alternative prefilled saline syringe options, combined with ongoing supply, transportation and labor challenges, we anticipate that this recall may contribute to a market disruption of prefilled saline syringes. We are actively working to address the disruption and support customers’ needs with locating alternative supply and we suggest that clinicians work with their facility to determine alternative fill methods.

For more information and the latest updates, please visit cardinalhealth.com/MonojectFlushPrefilledSalineSyringesIssue.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Contacts
Media: Andrew Stern, andrew.stern@cardinalhealth.com and (614) 339-4678

More Company News
03/26/2024

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will...

03/15/2024

Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions...

02/29/2024

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...

02/28/2024

Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years...

View all company news »